AbbVie’s Acquisition of Landos Marks a Strategic Move in Autoimmune Disease Treatment Development
AbbVie Inc. (ABBV) has announced a definitive agreement to acquire Landos Biopharma, Inc. (LABP), a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for autoimmune diseases. The acquisition signals AbbVie’s commitment to advancing innovative treatments for conditions like ulcerative colitis (UC) and Crohn’s disease.
Central to this acquisition is Landos’ lead investigational asset, NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action. NX-13 shows promise in addressing inflammation and facilitating epithelial repair, offering a novel approach to treating autoimmune diseases.
Roopal Thakkar, M.D., Senior Vice President and Chief Medical Officer of Global Therapeutics at AbbVie, expressed optimism about the potential of NX-13 to impact the lives of patients with UC and Crohn’s disease. The acquisition reflects AbbVie’s dedication to advancing therapies that address unmet medical needs in autoimmune diseases.
Gregory Oakes, President and CEO of Landos, highlighted the significance of this agreement, underscoring the potential of NX-13 to fill therapeutic gaps in the treatment landscape. Landos’ expertise, combined with AbbVie’s leadership in therapeutic areas and global development, positions the companies for significant progress in autoimmune disease treatment.
The proposed transaction, valued at approximately $212.5 million, is subject to customary closing conditions, including approval by Landos’ stockholders, and is expected to close in the second quarter of 2024. As AbbVie moves forward with this acquisition, the collaboration between the two companies holds promise for advancing innovative therapies and improving outcomes for patients with autoimmune diseases.
You might like this article:Disney Stock Surges on Wall Street Upgrade
